Skip to main content
GNMLF logo

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Stock Price & Analysis

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) — price $0.85 (0.00%), as of the Nov 18, 2026 trading session; market cap $831M.

Educational signal · not a buy or sell recommendation · How to read this

$0.85 $0.00 (0.00%) Market Cap $831M

Genomma Lab Internacional, S.A.B. de C.V. · GNMLF

Genomma Lab Internacional, S.A.B. de C.V. is a leading developer and marketer of over-the-counter pharmaceutical and personal care products in Mexico and internationally. The company offers a diverse range of products across various health and wellness categories, supported by a strong market presence and brand portfolio.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PFE · Pfizer Inc. · 67 /100
  • JNJ · Johnson & Johnson · 83 /100
  • BMY · Bristol-Myers Squibb Company · 85 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.85
Change on the day0.00%
52-week range$0.685 – $1.08
Market capitalisation$831M
Price / earnings (trailing)8.82
Shares traded on the day4.0K

Price & events

Other perspectives

Council score for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Negative
Debt/Equity Weak
ROE Moderate
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Genomma Lab Internacional, S.A.B. de C.V. (GNMLF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) is the company analyzed here. It employs 1,465 people and is led by Juan Marco Sparvieri. In Q3 FY2026 it reported revenue of MX$4.23B and net income of MX$484M. The market values it at $831M.

2 · Latest results

What do the latest results show for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of MX$4.23B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026MX$4.23BMX$484MMX$0.48 (diluted)
Q2 FY2026MX$4.39BMX$374MMX$0.37 (diluted)
Q1 FY2026MX$4.18BMX$493MMX$0.51 (diluted)
Q4 FY2025MX$4.01BMX$319MMX$0.33 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

Short answer · as of

The distress and quality screens read Altman Z 2.77 · Piotroski F 4. Trailing ratios: ROE 14.5% · ROA 6.7% · current ratio 1.75 · earnings yield 10.6% · free-cash-flow yield 9.0%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GNMLF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported GNMLF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)?

Read these with our analysis →

Common Questions About GNMLF

These answers are editorial: 3 of these 8 answers are drawn from the GNMLF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 5 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is GNMLF a good stock to buy?

Stock Expert AI does not rate GNMLF buy, sell or hold. Genomma Lab Internacional, S.A.B. de C.V. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the GNMLF stock price today?

The last price recorded for Genomma Lab Internacional, S.A.B. de C.V. (GNMLF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Genomma Lab Internacional, S.A.B. de C.V. do?

de C.V. develops and markets a wide range of over-the-counter pharmaceutical and personal care products. The company focuses on health and wellness, offering products in categories such as skin care, hair care, pain relief, and cough and cold remedies.

What are the key growth opportunities for GNMLF in healthcare?

de C.V. has several key growth opportunities, including expansion into emerging markets where demand for OTC products is increasing.

What are the main risks for GNMLF?

de C.V. faces several risks, including intense competition from both established and new entrants in the healthcare market.

What are the key factors to evaluate for GNMLF?

Evaluate GNMLF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Product Line Diversification: The company can enhance its product offerings by developing new formulations and entering additional therapeutic areas. Not financial advice.

How frequently does GNMLF data refresh on this page?

GNMLF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven GNMLF's recent stock price performance?

de C.V. (GNMLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence in the OTC pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.